Current Illinois CancerCare Clinical Trials

Milademetan in Advanced/​Metastatic Solid Tumors

Study Number: RAIN-3202 (JIT)

Study Summary:
Phase 2, multicenter, single-arm, open-label basket study designed to evaluate the safety and efficacy of milademetan in patients with advanced or metastatic solid tumors refractory or intolerant to standard-of-care therapy that exhibit wild-type (WT) TP53 and MDM2 copy number (CN) ≥ 8 using prespecified biomarker criteria.

Status: Open

Study Coordinator(s)
  • Navigator Ashton, 309-243-3611 atodd@illinoiscancercare.com
  • Navigator Carrie, 309-243-3621 cgeoffroy@illinoiscancercare.com
  • Navigator Angie, 309-243-3613, aearles@illinoiscancercare.com

Study Link

« Search Again
WordPress PopUp Plugin